BIRMINGHAM, Ala.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. today announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.
